<DOC>
	<DOCNO>NCT00080236</DOCNO>
	<brief_summary>The purpose study test safety effectiveness IDN-6556 preventing liver damage normally occur liver transport transplanted immediate post-transplant period .</brief_summary>
	<brief_title>Safety Efficacy Study Caspase Inhibitor Patients Undergoing Liver Transplantation</brief_title>
	<detailed_description>The occurrence apoptosis liver ischemia/reperfusion injury well characterize animal model . In context apoptosis specifically observe sinusoidal endothelial cell hepatocytes , also associate increase activate caspase-3 liver tissue extract . The use caspase inhibitor prevent apoptosis liver storage transplantation may reduce ischemia/reperfusion injury hence improve graft function transplantation . Suppression apoptosis caspase inhibitor may also allow long ischemic time allow organ transport great distance . In addition , suppression apoptosis may lower risk involve use suboptimal donor organ .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Caspase Inhibitors</mesh_term>
	<criteria>Minimum adult age Fulminant hepatic failure ( UNOS Status I patient ) Previous liver transplantation Patients undergoing split liver grafts Extrahepatic malignancy If female , pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Liver Transplantation</keyword>
</DOC>